Assetmark Inc. Raises Stake in IQVIA Holdings Inc. (NYSE:IQV)

Assetmark Inc. raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 612.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 228 shares of the medical research company’s stock after acquiring an additional 196 shares during the quarter. Assetmark Inc.’s holdings in IQVIA were worth $54,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Capital Performance Advisors LLP purchased a new stake in shares of IQVIA during the 3rd quarter worth approximately $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA during the 3rd quarter worth approximately $28,000. Versant Capital Management Inc lifted its position in shares of IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after buying an additional 110 shares during the last quarter. Opal Wealth Advisors LLC purchased a new stake in shares of IQVIA during the 2nd quarter worth approximately $27,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of IQVIA during the 2nd quarter worth approximately $29,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 6.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Price Performance

Shares of NYSE IQV opened at $191.19 on Tuesday. The firm has a market capitalization of $34.70 billion, a P/E ratio of 25.09, a PEG ratio of 1.98 and a beta of 1.51. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company’s fifty day moving average is $225.96 and its two-hundred day moving average is $228.02. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

Analyst Ratings Changes

Several analysts have recently weighed in on IQV shares. The Goldman Sachs Group reduced their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. BTIG Research cut their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a report on Friday, November 1st. Finally, Barclays cut their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Five analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $259.13.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.